ClinicalPractice
29.KhellafM,ViallardJF,HamidouM,mentofprimaryimmunethrombocytope-mentofchronicITP?AmJHematol2008;
etal.Aretrospectivepilotevaluationofnia:asystematicreviewandmeta-analysis.83:91.
switchingthrombopoieticreceptor-ago-LancetHaematol2015;2(2):e75-81.48.QuY,XuJ,JiaoC,ChengZ,RenS.
nistsinimmunethrombocytopenia.Hae-39.LucchiniE,ZajaF,BusselJ.Rituxi-Long-termoutcomesoflaparoscopicsple-
matologica2013;98:881-7.mabinthetreatmentofimmunethrom-nectomyversusopensplenectomyfor
30.González-PorrasJR,Mingot-Castellanobocytopenia:whatistheroleofthisagentidiopathicthrombocytopenicpurpura.Int
ME,AndradeMM,etal.Useofeltrombopagin2019?Haematologica2019;104:1124-35.Surg2014;99:286-90.
afterromiplostiminprimaryimmune40.PatelVL,MahévasM,LeeSY,etal.49.ThomsenRW,SchoonenWM,Farkas
thrombocytopenia.BrJHaematol2015;Outcomes5yearsafterresponsetorituxi-DK,RiisA,FryzekJP,S?rensenHT.Risk
169:111-6.mabtherapyinchildrenandadultswithofvenousthromboembolisminsplenec-
31.NewlandA,GodeauB,PriegoV,etal.immunethrombocytopenia.Blood2012;tomizedpatientscomparedwiththegen-
Remissionandplateletresponseswith119:5989-95.eralpopulationandappendectomizedpa-
romiplostiminprimaryimmunethrom-41.GhanimaW,KhelifA,WaageA,etal.tients:a10-yearnationwidecohortstudy.
bocytopenia:finalresultsfromaphase2Rituximabassecond-linetreatmentforJThrombHaemost2010;8:1413-6.
study.BrJHaematol2016;172:262-73.adultimmunethrombocytopenia(theRITP50.N?rgaardM,CetinK,MaegbaekML,
32.González-LópezTJ,PascualC,álvarez-trial):amulticentre,randomised,double-etal.Riskofarterialthromboticandve-
RománMT,etal.Successfuldiscontinua-blind,placebo-controlledtrial.Lancetnousthromboemboliceventsinpatients
tionofeltrombopagaftercompleteremis-2015;385:1653-61.withprimarychronicimmunethrombo-
sioninpatientswithprimaryimmune42.KhellafM,Charles-NelsonA,FainO,cytopenia:aScandinavianpopulation-
thrombocytopenia.AmJHematol2015;etal.Safetyandefficacyofrituximabinbasedcohortstudy.BrJHaematol2016;
90(3):E40-E43.adultimmunethrombocytopenia:results174:639-42.
33.GhanimaW,CooperN,RodeghieroF,fromaprospectiveregistryincluding24851.BoyleS,WhiteRH,BrunsonA,WunT.
GodeauB,BusselJB.Thrombopoietinre-patients.Blood2014;124:3228-36.Splenectomyandtheincidenceofvenous
ceptoragonists:tenyearslater.Haemato-43.BusselJ,ArnoldDM,GrossbardE,thromboembolismandsepsisinpatients
logica2019;104:1112-23.etal.Fostamatinibforthetreatmentofwithimmunethrombocytopenia.Blood
34.WongRSM,SalehMN,KhelifA,etal.adultpersistentandchronicimmune2013;121:4782-90.
Safetyandefficacyoflong-termtreat-thrombocytopenia:resultsoftwophase3,52.R?rholtM,GhanimaW,FarkasDK,
mentofchronic/persistentITPwithrandomized,placebo-controlledtrials.AmN?rgaardM.Riskofcardiovascular
eltrombopag:finalresultsoftheEXTENDJHematol2018;93:921-30.eventsandpulmonaryhypertensionfol-
study.Blood2017;130:2527-36.44.KojouriK,VeselySK,TerrellDR,lowingsplenectomy—aDanishpopula-
35.KuterDJ,BusselJB,NewlandA,etal.GeorgeJN.Splenectomyforadultpatientstion-basedcohortstudyfrom1996-2012.
Long-termtreatmentwithromiplostiminwithidiopathicthrombocytopenicpur-Haematologica2017;102:1333-41.
patientswithchronicimmunethrombo-pura:asystematicreviewtoassesslong-53.YongM,ThomsenRW,SchoonenWM,
cytopenia:safetyandefficacy.BrJHae-termplateletcountresponses,predictionetal.Mortalityriskinsplenectomisedpa-
matol2013;161:411-23.ofresponse,andsurgicalcomplications.tients:aDanishpopulation-basedcohort
36.JurczakW,ChojnowskiK,MayerJ,Blood2004;104:2623-34.study.EurJInternMed2010;21:12-6.
etal.Phase3randomisedstudyofava-45.ChaturvediS,ArnoldDM,McCrae54.ParkYH,YiHG,KimCS,etal.Clini-
trombopag,anovelthrombopoietinrecep-KR.Splenectomyforimmunethrombocy-caloutcomeandpredictivefactorsinthe
toragonistforthetreatmentofchronictopenia:downbutnotout.Blood2018;responsetosplenectomyinelderlypa-
immunethrombocytopenia.BrJHaema-131:1172-82.tientswithprimaryimmunethrombocy-
tol2018;183:479-90.46.MatzdorffA,MeyerO,OstermannH,topenia:amulticenterretrospectivestudy.
37.ArnoldDM,DentaliF,CrowtherMA,etal.Immunethrombocytopenia—cur-ActaHaematol2016;135:162-71.
etal.Systematicreview:efficacyandsafe-rentdiagnosticsandtherapy:recommen-55.NeunertCE,CooperN.Evidence-
tyofrituximabforadultswithidiopathicdationsofajointworkinggroupofbasedmanagementofimmunethrombo-
thrombocytopenicpurpura.AnnInternDGHO,?GHO,SGH,GPOH,andDGTI.cytopenia:ASHguidelineupdate.Hema-
Med2007;146:25-33.OncolResTreat2018;41:Suppl5:1-30.tologyAmSocHematolEducProgram
38.ChughS,Darvish-KazemS,LimW,etal.47.RodeghieroF,RuggeriM.Issplenec-2018;2018:568-75.
Rituximabplusstandardofcarefortreat-tomystillthegoldstandardforthetreat-Copyright?2019MassachusettsMedicalSociety.
955
nengljmed381;10nejm.orgSeptember5,2019
TheNewEnglandJournalofMedicine
Downloadedfromnejm.orgatSHANGHAIJIAOTONGUNIVERSITYSCHOOLOFMEDICINEonOctober9,2021.Forpersonaluseonly.Nootheruseswithoutpermission.
Copyright?2019MassachusettsMedicalSociety.Allrightsreserved. |
|
